Search Results - "Santini, D."

Management of cancer pain: ESMO Clinical Practice Guidelines by Ripamonti, C I, Santini, D, Maranzano, E, Berti, M, Roila, F

Get full text

Bone health in cancer: ESMO Clinical Practice Guidelines by Coleman, R., Hadji, P., Body, J.-J., Santini, D., Chow, E., Terpos, E., Oudard, S., Bruland, Ø., Flamen, P., Kurth, A., Van Poznak, C., Aapro, M., Jordan, K.

“…•The clinical course of advanced cancer for many patients with bone metastases can be transformed through optimum multidisciplinary management.•Bone-targeted…”
Get full text

The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline by Di Maio, M., Basch, E., Denis, F., Fallowfield, L.J., Ganz, P.A., Howell, D., Kowalski, C., Perrone, F., Stover, A.M., Sundaresan, P., Warrington, L., Zhang, L., Apostolidis, K., Freeman-Daily, J., Ripamonti, C.I., Santini, D.

“…•This ESMO Guideline provides key recommendations on the role of PROMs during the care of patients with cancer.•It covers the use of PROMs in patients with…”
Get full text

PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises by Massari, F, Santoni, M, Ciccarese, C, Santini, D, Alfieri, S, Martignoni, G, Brunelli, M, Piva, F, Berardi, R, Montironi, R, Porta, C, Cascinu, S, Tortora, G

“…Highlights • Evasion of immune surveillance, a process defined immune-editing, leads to RCC malignant progression. • The PD-1/PD-L1 axis inhibition by…”
Get full text

Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO by Dell’Aquila, E., Cremolini, C., Zeppola, T., Lonardi, S., Bergamo, F., Masi, G., Stellato, M., Marmorino, F., Schirripa, M., Urbano, F., Ronzoni, M., Tomasello, G., Zaniboni, A., Racca, P., Buonadonna, A., Allegrini, G., Fea, E., Di Donato, S., Chiara, S., Tonini, G., Tomcikova, D., Boni, L., Falcone, A., Santini, D.

“…Neutrophil/lymphocyte ratio (NLR), defined as absolute neutrophils count divided by absolute lymphocytes count, has been reported as poor prognostic factor in…”
Get full text

Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines by Lacouture, M.E., Sibaud, V., Gerber, P.A., van den Hurk, C., Fernández-Peñas, P., Santini, D., Jahn, F., Jordan, K.

“…•This ESMO Clinical Practice Guideline provides recommendations on the prevention/management of dermatological toxicities.•Authorship includes a…”
Get full text

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer by Loupakis, F, Ruzzo, A, Cremolini, C, Vincenzi, B, Salvatore, L, Santini, D, Masi, G, Stasi, I, Canestrari, E, Rulli, E, Floriani, I, Bencardino, K, Galluccio, N, Catalano, V, Tonini, G, Magnani, M, Fontanini, G, Basolo, F, Falcone, A, Graziano, F

“…Background: KRAS codons 12 and 13 mutations predict resistance to anti-EGFR monoclonal antibodies (moAbs) in metastatic colorectal cancer. Also, BRAF V600E…”
Get full text

Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? by Santini, D., Vincenzi, B., Addeo, R., Garufi, C., Masi, G., Scartozzi, M., Mancuso, A., Frezza, A.M., Venditti, O., Imperatori, M., Schiavon, G., Bronte, G., Cicero, G., Recine, F., Maiello, E., Cascinu, S., Russo, A., Falcone, A., Tonini, G.

“…Scientific data provide the evidence that secondary K-RAS mutations do not occur during anti-epidermal growth factor receptor therapy in colorectal cancer…”
Get full text

Tissue invasion and metastasis: Molecular, biological and clinical perspectives by Jiang, W.G, Sanders, A.J, Katoh, M, Ungefroren, H, Gieseler, F, Prince, M, Thompson, S.K, Zollo, M, Spano, D, Dhawan, P, Sliva, D, Subbarayan, P.R, Sarkar, M, Honoki, K, Fujii, H, Georgakilas, A.G, Amedei, A, Niccolai, E, Amin, A, Ashraf, S.S, Ye, L, Helferich, W.G, Yang, X, Boosani, C.S, Guha, G, Ciriolo, M.R, Aquilano, K, Chen, S, Azmi, A.S, Keith, W.N, Bilsland, A, Bhakta, D, Halicka, D, Nowsheen, S, Pantano, F, Santini, D

“…Abstract Cancer is a key health issue across the world, causing substantial patient morbidity and mortality. Patient prognosis is tightly linked with…”
Get full text

Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment by Fioramonti, M., Fausti, V., Pantano, F., Iuliani, M., Ribelli, G., Lotti, F., Pignochino, Y., Grignani, G., Santini, D., Tonini, G., Vincenzi, B.

“…Osteosarcoma (OS) is the most common primary malignant tumor of the bone. Due to its high heterogeneity and to survival signals from bone microenvironment, OS…”
Get full text

Novel drugs, familiar interactions: ciprofloxacin may increase exposure to the RET inhibitor pralsetinib by Citarella, F., Russano, M., Galletti, A., Vincenzi, B., Tonini, G., Santini, D.

Get full text

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel by Hadji, P., Coleman, R.E., Wilson, C., Powles, T.J., Clézardin, P., Aapro, M., Costa, L., Body, J.-J., Markopoulos, C., Santini, D., Diel, I., Di Leo, A., Cameron, D., Dodwell, D., Smith, I., Gnant, M., Gray, R., Harbeck, N., Thurlimann, B., Untch, M., Cortes, J., Martin, M., Albert, U.-S., Conte, P.-F., Ejlertsen, B., Bergh, J., Kaufmann, M., Holen, I.

“…Bisphosphonates have been studied in randomised trials in early breast cancer to investigate their ability to prevent cancer treatment-induced bone loss…”
Get full text

Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer by Cursano, M. C., Conteduca, V., Scarpi, E., Gurioli, G., Casadei, C., Gargiulo, S., Altavilla, A., Lolli, C., Vincenzi, B., Tonini, G., Santini, D., De Giorgi, U.

“…In localized prostate cancer (PCa), Grade Group (GG) and Gleason Score (GS) have a well-established prognostic role. In metastatic castration resistant…”
Get full text

The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies by Russo, A., Incorvaia, L., Del Re, M., Malapelle, U., Capoluongo, E., Gristina, V., Castiglia, M., Danesi, R., Fassan, M., Giuffrè, G., Gori, S., Marchetti, A., Normanno, N., Pinto, C., Rossi, G., Santini, D., Sartore-Bianchi, A., Silvestris, N., Tagliaferri, P., Troncone, G., Cinieri, S., Beretta, G.D.

“…The term liquid biopsy (LB) refers to the use of various biological fluids as a surrogate for neoplastic tissue to achieve information for diagnostic,…”
Get full text

Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review by Cursano, M.C., Iuliani, M., Casadei, C., Stellato, M., Tonini, G., Paganelli, G., Santini, D., De Giorgi, U.

“…•In bone mCRPC, each treatment has an effect on PCa cells and bone microenvironment.•Clinical trials have been performed to evaluate radium 223-based…”
Get full text

Role of molecular genetics in the clinical management of cholangiocarcinoma by Normanno, N., Martinelli, E., Melisi, D., Pinto, C., Rimassa, L., Santini, D., Scarpa, A.

“…The incidence of cholangiocarcinoma (CCA) has steadily increased during the past 20 years, and mortality is increasing. The majority of patients with CCA have…”
Get full text

Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer by Fornaro, L, Cereda, S, Aprile, G, Di Girolamo, S, Santini, D, Silvestris, N, Lonardi, S, Leone, F, Milella, M, Vivaldi, C, Belli, C, Bergamo, F, Lutrino, S E, Filippi, R, Russano, M, Vaccaro, V, Brunetti, A E, Rotella, V, Falcone, A, Barbera, M A, Corbelli, J, Fasola, G, Aglietta, M, Zagonel, V, Reni, M, Vasile, E, Brandi, G

“…Background: The role of second-line chemotherapy (CT) is not established in advanced biliary tract cancer (aBTC). We investigated the outcome of aBTC patients…”
Get full text

KRAS G12C mutation and risk of disease recurrence in stage I surgically resected lung adenocarcinoma by Gallina, F.T., Marinelli, D., Melis, E., Forcella, D., Taje, R., Buglioni, S., Visca, P., Torchia, A., Cecere, F.L., Botticelli, A., Santini, D., Ciliberto, G., Cappuzzo, F., Facciolo, F.

“…•It is unclear whether the KRAS G12C has a prognostic role in early stage LUAD.•In the stage I IRE cohort we found an association between KRAS G12C and worse…”
Get full text

First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin by Iacovelli, R., Ciccarese, C., Brunelli, M., Battelli, N., Buttigliero, C., Caserta, C., Buti, S., Santini, D., Carella, C., Galli, L., Verri, E., Ermacora, P., Merler, S., Masini, C., De Vivo, R., Milesi, L., Spina, F., Rizzo, M., Sperduti, I., Fornarini, G., Tortora, G.

“…Cisplatin-based chemotherapy is the most recommended treatment for metastatic urothelial cancer (mUC). However, about 50% of patients are considered to be…”
Get full text

The use of SAMe in chemotherapy-induced liver injury by Vincenzi, B., Russo, A., Terenzio, A., Galvano, A., Santini, D., Vorini, F., Antonelli-Incalzi, R., Vespasiani-Gentilucci, U., Tonini, G.

“…Drug-induced liver injury (DILI) remains the most common cause of acute liver failure in the Western world. Chemotherapy is one of the major class of drugs…”
Get full text